
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : OpCT-001
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
BlueRock Exercise Option to License FUJIFILM's OpCT-001 for Primary Photoreceptor Disease
Details : Under the agreement, BlueRock exercised its option to exclusively license OpCT-001, an induced pluripotent stem cell (iPSC) derived cell therapy candidate for primary photoreceptor diseases.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 23, 2024
Lead Product(s) : OpCT-001
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : BlueRock Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery
Sponsor : Century Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The agreement aims for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery
Sponsor : Century Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
